The tumour-node-metastasis classification has been widely used as a guide for estimating prognosis, and is the basis for treatment decisions in patients with malignant tumours. The International Association for the Study of Lung Cancer Staging and Prognostic Factors Committee and the International Thymic Malignancy Interest Group have proposed a new staging system for thymic malignancies. However, its validity has not been fully established. In this study, we assessed the system's utilities and drawbacks.
INTRODUCTION
The tumour-node-metastasis (TNM) classification of cancers proposed by Union for International Cancer Control (UICC) and the American Joint Committee on Cancer (AJCC) has been widely accepted as a guide for estimating patient prognosis, and it is the basis for treatment decisions undertaken in clinical practice. At least 15 different stage classification systems for thymic tumours have been proposed and implemented [1] [2] [3] [4] [5] [6] [7] . The four-tiered Masaoka staging system was proposed in 1981 [8] , and a modification of this classification was suggested by Koga et al. in 1994 [9] . This system has been the most widely used, and many investigators who state that they use the 'Masaoka system' are in fact using the Koga modification. However, no classification and staging system has been approved by the UICC and AJCC. In 2009, both the International Association for the Study of Lung Cancer (IASLC) and the International Thymic Malignancy Interest Group (ITMIG) recognized the need for a consistent stage classification system for thymic malignancies. Recently, these bodies developed proposals for the TNM classification of thymic malignancies, which were published in advance of the official staging system of the forthcoming 8th edition of the TNM classification. The new proposals were based on the large amount of data available on the global database created by the ITMIG, which consisted of 8145 patients [10] [11] [12] [13] [14] .
The purpose of this retrospective study was to review the clinical characteristics of patients based on the new staging system proposed by the IASLC/ITMIG. We studied 154 consecutive patients who underwent complete resection at Nagoya University Hospital, Japan. This is the first report, to our knowledge, which discusses the utilities and drawbacks of the new staging system.
PATIENTS AND METHODS

Patients
Approval for this study was obtained from the institutional review board of Nagoya University Hospital, which waived the requirement for individual patient consent. Between 2001 and 2014, 181 consecutive patients with thymic epithelial tumours underwent surgical resection. After 22 patients with recurrence and 5 who underwent R2 resection were excluded, 154 patients were ultimately enrolled in this study, and their clinicopathological features and outcomes were retrospectively evaluated. The data extracted from each patient's medical record included age, sex, tumour histology according to the WHO classification [15] , tumour size, surgical procedure performed, Masaoka-Koga stage, date of last follow-up and death from any cause. The MasaokaKoga stage was based on the definition published in 2011 [16] . The mean patient follow-up period was 45 months. Detailed patients' characteristics in this cohort are provided in Table 1 . The resected tumours were reviewed and diagnosed by the preeminent pathologist and thymus expert. Invasion to the mediastinal pleura or neighbouring structures in all the tumours was confirmed microscopically. Recurrence was mainly diagnosed by radiographic evaluations including chest X-ray and computed tomography (CT) which were routinely performed during the postoperative follow-up period and confirmed by positron emission tomography/CT.
Proposed staging system
The newly proposed TNM staging system criteria for thymic malignancies by the IASLC/ITMIG are summarized in Table 2 . Concerning the T descriptor, the IASLC/ITMIG proposed that tumours that are totally encapsulated, extend into the mediastinal fat tissue and invade into the mediastinal pleura be defined collectively as T1 tumours. T2 tumours are defined as those that invade into the pericardium only. T3 and T4 tumours invade into intrathoracic structures such as large vessels, lung parenchyma and other tissues ( 
Survival analysis
The Kaplan-Meier method was used to plot survival curves, and the log-rank test was used to evaluate differences between subgroups. To perform the statistical evaluation of the two staging systems, we estimated the hazard ratio for each group in the two systems using the Cox regression analysis. The threshold of significance was set at P < 0.05. Statistical calculations were performed with a statistical software package (StatView version 5.0; SAS Institute, Inc., Cary, NC, USA).
RESULTS
Distribution of the pathological stage
According to the Masaoka-Koga system, patients were distributed by disease stage, as follows: Stage I, n = 38 (24.7%); Stage IIA, n = 61 (39.6%); Stage IIB, n = 10 (6.5%); Stage III, n = 32 (20.8%); Stage IVA, n = 4 (2.6%); Stage IVB, n = 9 (5.8%). Under the proposed new system, patients were distributed as follows: Stage I, n = 119 (77.3%); Stage II, n = 4 (2.6%); Stage IIIA, n = 17 (11.0%); Stage IIIB, n = 1 (0.6%); Stage IVA, n = 9 (5.8%); Stage IVB, n = 4 (2.6%) (Fig. 1) . When comparing these distributions, the proportion of patients (Table 3 ).
The stage distribution under the proposed system as stratified by the WHO histological classification of thymic epithelial tumours is shown in Fig. 2 . Among the 69 patients diagnosed with Type A, AB or B1 thymoma, 68 tumours (98%) were classified as Stage I disease. Furthermore, the proportion of Stage III and IV tumours increased in the same order of Type B2, B3 thymoma and thymic carcinoma (Fig. 2) .
Survival analysis
As first, overall survival curves according to the Masaoka-Koga and proposed staging systems are shown in Fig. 3 . The 5-year survival rates of the patients with Stage I disease were 94.1 and 94.2%, respectively, in this cohort, being almost identical. Although significant differences were observed in the new system (P < 0.0001), the survival curves did not show stepwise deterioration as the stage increased in either system. Next, we analysed the recurrence-free survival characteristics and observed prognostic differences between the stages of the both systems (Fig. 4) . However, with the proposed new system, the survival curves showed significant deterioration of prognosis as the stage increased ( Fig. 4B , P < 0.0001). The 5-year recurrence-free survival rate of 119 patients with Stage I disease under the proposed system was 90.5%, whereas the rate was 51.4% in 35 patients with Stage II, III and IV disease (P < 0.0001). In addition, the hazard ratios for each group in the two systems using the Cox regression analysis are presented in Table 4 . With the new system, hazard ratios for recurrence-free survival also showed significant deterioration as the stage increased except for the patients with Stage IIIB. 
DISCUSSION
The staging system for cancer according to the TNM classification is an accepted principle used globally by oncologists. It serves many purposes including providing indication of prognosis, planning of treatments, evaluating the results of treatments, facilitating the exchange of information among institutions and facilitating to the continued investigation of human cancers [17] . There has been no classification and staging system for thymic epithelial tumours approved by the UICC and AJCC, although the Masaoka-Koga system has been widely used for decades [8] [9] . Recently, the IASLC/ITMIG developed proposals regarding a TNM classification for thymic malignancies to be included in the new official staging system of the forthcoming 8th edition of the TNM classification [11] [12] [13] [14] . In this study, we clinically evaluated the proposed TNM classification in 154 patients with thymic epithelial tumours. To our knowledge, this is the first report to evaluate and validate the proposed system using the data derived from completely resected thymic epithelial tumours.
When analysing stage distribution according to the proposed system, we observed that the proportion of patients with Stage I disease dramatically increased from 24.7 to 77.3% because of the down-staging of patients with Masaoka-Koga stage II and III disease (Fig. 1) . Conversely, only four tumours (2.6%) were reclassified as Stage II. A worldwide database created by the ITMIG (n = 4492) revealed the tumour distribution to be as follows: Stage I, 81.5%; Stage II, 2.8%; Stage IIIA, 10.1%; Stage IIIB, 0.4%; Stage IVA, 4.5% and Stage IVB, 0.8% [13] ; this was quite similar to that of our cohort. The imbalance of the distribution of stages was owing to disregarding whether a tumour was encapsulated or invading into the thymus and perithymic fat tissue in the proposed T descriptors. The new definition of T1 tumours enabled us to evaluate most lesions in a clinical setting, including preoperative radiological evaluation, whereas the Masaoka-Koga classification was mainly based on pathological findings. Detterbeck et al. claimed that whether the tumour was encapsulated or not had little clinical impact, although mediastinal pleural involvement was a further testing factor [13] . Among 10 patients with mediastinal pleural invasion only, no patient experienced recurrence or died of tumour. Thus, the down-staging of these tumours to Stage I appeared to be appropriate for our cohort.
In this study, the recurrence-free survival curves showed significant deterioration as the stages as defined by the proposed system increased, whereas the overall survival curves did not. Recurrence is thought to be the best measure of outcome, especially for thymomas, which are rarely lethal and have slow progression. The definitions of the proposed T, N and M descriptors and stage groupings were based heavily on patient survival, i.e. on the concept of 'prognostic grouping' of the recent TNM classification. However, the prognosis is complex and influenced by several factors. Therefore, stage grouping, which may accurately show recurrence-free survival, appears to be much more relevant for thymic epithelial tumours. In the proposed system as well as the Masaoka-Koga system, the tumour size is not included in the definition of the T descriptor [8] [9] 11] . The T descriptor is only defined by the anatomical extent of primary tumours. Therefore, unless the tumour invades the neighbouring structures such as the pericardium, lungs or large vessels, it is classified as T1 regardless of its size. Indeed, the maximum sizes of the tumours classified as new T1 were widely distributed, ranging from 1.1 to 11.0 cm in our cohort. Among the TNM classification of common malignancies, the tumour size is included in the definition of the T descriptor in thyroid, breast, lung, liver, renal and pancreatic cancers. In lung cancer, since the maximum size of the primary tumour is a strong and significant prognostic factor, the T descriptor was defined mainly by the size, in which the cut-off values of 2, 3, 5 and 7 cm were adopted in the 7th TNM classification [17] . In thymic epithelial tumours, Nicholson et al. performed size analyses using the cohort from the ITMIG, showing no survival difference among completely resected patients [11] . However, the prognostic significance of the tumour size has not been still fully studied to date; it ought to be investigated.
Pathological diagnosis of thymic epithelial tumours according to the current WHO classification has been widely acknowledged to be variable, which was due to the heterogeneity of the cellular components in these tumours [18] . Sakakura et al. reported a high rate of discordance in diagnosing thymomas between an expert pathologist specialized in thymic pathology and a trained general pathologist [19] . Hence, the future of histopathological classification of thymomas appears to favour a more simplified classification system. Suster et al. proposed a three-tiered structure as follows: well-differentiated thymic carcinoma that includes Type A, AB, B1 and B2 thymoma per WHO classification; moderately differentiated thymic carcinoma that encompasses Type B3 and poorly differentiated thymic carcinoma that incorporates the current 'thymic carcinoma' classification [20] . Our study supports this proposed terminology. Among the 107 tumours diagnosed as Type A, AB, B1 or B2 thymoma, 95 (89%) were classified as Stage I disease. The proportions of Stage I disease were 55 and 38% in Type B3 and thymic carcinoma, respectively, which was significantly lower than that in the well-differentiated group (P < 0.0001). This study had some limitations. Firstly, because this was a retrospective cohort analysis from a single institution, several biases may have existed that could have influenced patient survival. In particular, the total number of patients was relatively small in our cohort to validate the newly proposed TNM system which was learned from the 8145 patients from the ITMIG database; a much larger cohort is essentially required for such analyses. However, whether the usefulness of the classification generated by a large cohort could be reproduced using a small cohort from a single institution is thought to be enough meaningful. Secondly, only completely resected tumours were included in this study; hence, the outcome of patients with advanced disease who did not undergo curative resection remains unclear. Additionally, the postoperative follow-up period might be relatively short for thymic malignancies, in which recurrence beyond 5 years post-surgery is quite common. In spite of these limitations, our study had the strong advantage of having our resected tumours reviewed and diagnosed by the expert pathologist of thymus.
The development of a new TNM classification for thymic malignancies is essential for clinicians specialized in the management of thoracic malignancies. The newly proposed system by the IASLC/ ITMIG, which was partly based on the current Masaoka-Koga system, appears to be functional and worthwhile, especially in clinical settings and recurrence-free survival analysis. However, the new convention could not serve as a prognostic prediction model for overall survival, and it did address the significant imbalances of stage distribution. Further investigation and validation of this new TNM classification for thymic malignancies using larger cohorts is warranted.
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